We are testing the drug teplizumab (Anti-CD3) to see if it can delay or prevent early stage T1D (stage 2) from progressing to clinical diagnosis (stage 3) In earlier studies  teplizumab helped people with a new T1D clinical diagnosis (stage 3) keep making their own insulin longer